Madrigal Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Madrigal Pharmaceuticals's earnings have been declining at an average annual rate of -30.7%, while the Biotechs industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 109.1% per year.
Key information
-30.7%
Earnings growth rate
-26.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 109.1% |
Return on equity | -59.6% |
Net Margin | -3,487.1% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher
Aug 09While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Dec 20We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 11Madrigal: NASH Data In Q4 Is The Key
Apr 19We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26Madrigal Pharmaceuticals: Leading The NASH Innovation
May 05Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
Apr 12We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
Dec 28Madrigal Pharma: A Look At The Early MAESTRO Trial Data
Nov 27Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
Nov 17Madrigal Pharmaceuticals EPS misses by $0.40
Nov 05Revenue & Expenses Breakdown
How Madrigal Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 15 | -510 | 260 | 284 |
31 Mar 24 | 0 | -444 | 173 | 281 |
31 Dec 23 | 0 | -374 | 108 | 272 |
30 Sep 23 | 0 | -347 | 76 | 272 |
30 Jun 23 | 0 | -330 | 61 | 270 |
31 Mar 23 | 0 | -315 | 55 | 260 |
31 Dec 22 | 0 | -295 | 48 | 245 |
30 Sep 22 | 0 | -274 | 45 | 228 |
30 Jun 22 | 0 | -256 | 41 | 214 |
31 Mar 22 | 0 | -247 | 40 | 207 |
31 Dec 21 | 0 | -242 | 37 | 205 |
30 Sep 21 | 0 | -236 | 32 | 206 |
30 Jun 21 | 0 | -231 | 29 | 204 |
31 Mar 21 | 0 | -219 | 24 | 197 |
31 Dec 20 | 0 | -202 | 22 | 185 |
30 Sep 20 | 0 | -171 | 21 | 156 |
30 Jun 20 | 0 | -134 | 20 | 122 |
31 Mar 20 | 0 | -105 | 22 | 93 |
31 Dec 19 | 0 | -84 | 23 | 72 |
30 Sep 19 | 0 | -68 | 23 | 56 |
30 Jun 19 | 0 | -55 | 24 | 43 |
31 Mar 19 | 0 | -42 | 19 | 33 |
31 Dec 18 | 0 | -33 | 15 | 25 |
30 Sep 18 | 0 | -30 | 12 | 23 |
30 Jun 18 | 0 | -30 | 9 | 24 |
31 Mar 18 | 0 | -32 | 8 | 25 |
31 Dec 17 | 0 | -31 | 8 | 24 |
30 Sep 17 | 0 | -30 | 7 | 23 |
30 Jun 17 | 0 | -36 | 9 | 25 |
31 Mar 17 | 0 | -31 | 8 | 20 |
31 Dec 16 | 0 | -26 | 7 | 16 |
30 Sep 16 | 0 | -21 | 5 | 11 |
30 Jun 16 | 0 | -8 | 1 | 4 |
31 Mar 16 | 0 | -7 | 1 | 3 |
31 Dec 15 | 0 | -7 | 1 | 2 |
Quality Earnings: MDGL is currently unprofitable.
Growing Profit Margin: MDGL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDGL is unprofitable, and losses have increased over the past 5 years at a rate of 30.7% per year.
Accelerating Growth: Unable to compare MDGL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDGL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-38.7%).
Return on Equity
High ROE: MDGL has a negative Return on Equity (-59.55%), as it is currently unprofitable.